Stay updated on Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe modernization of the ClinicalTrials.gov data ingest has been postponed to July 2025, and the expected duration of the treatment has been extended from approximately 60 months to 62 months. Additionally, the registry identifiers have been updated.SummaryDifference3%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check32 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.7%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check75 days agoChange DetectedThe page has been updated to include new identifiers related to the study of pembrolizumab for squamous cell carcinoma, while significant details about the study's design and criteria have been removed.SummaryDifference15%
Stay in the know with updates to Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial page.